Fighting cardiovascular disease with acne drug

Date:
September 8, 2020
Source:
European Molecular Biology Laboratory
Summary:
Researchers have found the cause of dilated cardiomyopathy -
a leading cause of heart failure - and identified a potential
treatment for it: a drug already used to treat acne.



FULL STORY ========================================================================== Dilated cardiomyopathy (DCM) is a leading cause of heart failure,
affecting 1 in 250 people. The disease is characterised by an increase in
size of the left ventricle of the heart. The stretched heart muscle is
then unable to pump blood as effectively, which can lead to irregular heartbeat, heart valve problems, and ultimately heart failure. As
the leading cause of heart failure, DCM is the most common reason for
carrying out a heart transplant, which is only offered in end-stage
heart failure when all other treatment options and lifestyle changes
have failed. Despite years of work to improve patient survival after transplantation, the 10-year survival rate is still only 50%.


========================================================================== "Currently DCM is treated with medicines used for heart failure in
general, their function being to lower strain on the heart. Patient
health would be significantly improved with targeted treatment options
prior to the need for a heart transplant," explains Lars Steinmetz, from
the European Molecular Biology Laboratory in Heidelberg and Stanford University. "We need therapeutic strategies that target the cause of
the disease in a personalised medicine approach." The new study by the Steinmetz group, in cooperation with Mark Mercola's lab at Stanford
University, provides fresh insight into this deadly disease, hinting at potential new treatment possibilities.

The researchers had the unique opportunity to study a single family with inherited DCM to understand the cause of their disease. Because it's an inherited disease, studying the genome, or complete set of DNA and genes,
can provide important information on the mutation causing the disease. By studying a family, the researchers were able to look for differences in
the regions of the genome that carry instructions for making proteins,
in family members who had died with a diagnosis of DCM, had been diagnosed
with DCM, or were unaffected by DCM. This comparison allowed them to find
a single mutation (P633L) in a gene coding for a protein called RBM20,
which was disease causing.

Although the mutation was previously unknown, changes in RBM20 are known
to cause a severe form of inherited DCM that is often associated with
early onset of end-stage heart failure.

"When we started the project, we wanted to identify the mutation causing
the disease in this family," explains Steinmetz, who is also the founder
of the Steinmetz Cardiomyopathy Fund, by which most of the study was
financed.

Francesca Briganti, from the Mercola Lab, adds: "When we found the new mutation, we had to demonstrate that this is indeed the pathogenic
mutation - there were already over 30 genes linked to the disease
beforehand. We did this by showing that the mutation causes splicing and cellular contraction defects using in vitro cell models." The researchers
used a combination of patient-derived cells and genome-edited cells. This process of genome editing involved making specific changes to the DNA of
the cells, to introduce the RBM20 mutation (P633L) into patient-derived
cells known as induced pluripotent stem cell-derived cardiomyocytes
(iPSC-CMs).

This gave the researchers the chance to understand how the mutation was
causing DCM and also to propose a potential treatment option. "We were
lucky. We searched the database and found a fitting compound. Going from finding the disease gene to finding the potential solution overnight was
easy with the open databases at EMBL's European Bioinformatics Institute,"
says Steinmetz.

The team identified a chemical called all-trans retinoic acid (ATRA) as a potential treatment of DCM. ATRA regulates RBM20, and can partially fix
the defects in the altered cells. ATRA is a drug used for the treatment
of acne and a type of leukaemia called acute promyelocytic leukaemia. In
this case, Steinmetz reasoned that increasing expression of RBM20 might overcome the insufficient expression of this protein that is seen in
patients who have one functioning and one mutated copy of the gene.

"This is a promising result in approaching RBM20-deficient DCM," explains Steinmetz. "In addition, the general approach and the strategy we used
in this study could work for a number of other dominant diseases!"

========================================================================== Story Source: Materials provided by
European_Molecular_Biology_Laboratory. Note: Content may be edited for
style and length.


========================================================================== Journal Reference:
1. Francesca Briganti, Han Sun, Wu Wei, Jingyan Wu, Chenchen Zhu,
Martin
Liss, Ioannis Karakikes, Shannon Rego, Andrea Cipriano, Michael
Snyder, Benjamin Meder, Zhenyu Xu, Gilles Millat, Michael Gotthardt,
Mark Mercola, Lars M. Steinmetz. iPSC Modeling of RBM20-Deficient
DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy. Cell
Reports, 2020; 32 (10): 108117 DOI: 10.1016/j.celrep.2020.108117 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2020/09/200908122502.htm

--- up 2 weeks, 1 day, 6 hours, 50 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)